MedTrace Logo

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

NCT02054052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-03-29

No results posted yet for this study

Summary

Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE

Sponsors & Collaborators

  • Haihong Yang, MD, Pricipal investigator

    lead OTHER

Principal Investigators

  • Haihong Yang, MD · the First Affiliated Hospital of Guangzhou MC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054052 on ClinicalTrials.gov